Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christopher Foti

Physician Assistant, Medical Wheeling, WV Physician Assistant

NPI 1770577389 CMS profile 10831117

76 16Th St Ste 100A, Wheeling, WV 26003

Open in the dashboard

General payments

$5,525

255 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Foti of Wheeling, WV is reported in the CMS Open Payments database as having received $5,525 across 255 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $731 33
2024 General $1,040 43
2023 General $1,549 75
2022 General $970 46
2021 General $1,234 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Foti
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Christopher Foti were reported at $731. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Christopher Foti Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,234 $156 $41–$563 $132
2022 $970 $185 $55–$649 $149
2023 $1,549 $199 $58–$717 $160
2024 $1,040 $206 $62–$740 $164
2025 $731 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Genzyme Corporation $882 36 payments
  2. Amgen Inc. $735 35 payments
  3. AbbVie, Inc. $703 34 payments
  4. Novartis Pharmaceuticals Corporation $502 27 payments
  5. Dermavant Sciences, Inc. $470 21 payments
  6. LEO Pharma Inc. $468 20 payments
  7. Regeneron Healthcare Solutions, Inc. $265 10 payments
  8. Arcutis Biotherapeutics, Inc. $256 13 payments
  9. E.R. Squibb & Sons, L.L.C. $223 13 payments
  10. UCB, Inc. $181 9 payments
  11. Other $838 37 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,380 253 payments
  2. Education $145 2 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,049 40 payments
  2. Otezla $735 35 payments
  3. SKYRIZI $499 24 payments
  4. VTAMA $470 21 payments
  5. ADBRY $424 18 payments
  6. COSENTYX $297 16 payments
  7. DUPIXENT Inflammation And Immunology $265 10 payments
  8. Enbrel $240 12 payments
  9. SOTYKTU $223 13 payments
  10. AKLIEF $158 5 payments
  11. Other $1,898 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,224

Median for Physician Assistant: 241

Drug cost

$984,705

Median for Physician Assistant: $4,110

Branded share of claims

18.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Risankizumab-Rzaa Brand 18 $372,667
Humira(Cf) Pen Adalimumab Brand 28 $283,080
Otezla Apremilast Brand 39 $186,441
Dupixent Syringe Dupilumab Brand 30 $112,565
Metronidazole Generic 51 $4,374
Triamcinolone Acetonide Generic 260 $4,197
Clobetasol Propionate Generic 96 $4,133
Tacrolimus Generic 23 $3,034
Ketoconazole Generic 142 $2,502
Valacyclovir Valacyclovir Hcl Brand 39 $2,068

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$96,440

Medicare's payments for the services billed

Medicare patients

544

Average age 74

Services billed

2,880

285 women, 259 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 23%
Ischemic heart disease 22%
Depression 19%
Atrial fibrillation 15%
Chronic kidney disease 13%
Cancer 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $314
  • SANOFI-AVENTIS U.S. LLC $72
$386 30 —
Otezla
  • Amgen Inc. $151
$151 39 —
VTAMA
  • Dermavant Sciences, Inc. $138
$138 — —
SKYRIZI
  • AbbVie, Inc. $120
$120 18 —
Zoryve
  • Arcutis Biotherapeutics, Inc. $82
$82 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

255 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record